We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 28.82 | 0 | 01:00:00 |
From May 2019 to May 2024
Gemphire Therapeutics Inc. (GEMP) saw its shares drop by over 50% in Friday trading, after the company announced the termination of a clinical trial of gemcabene. At 10:51 a.m. EDT, Gemphire shares had fallen to $1.38, down 57.80%, in heavy trading. Earlier in the week, the company announced it amended an agreement with Pfizer, Inc. concerning gemcabene. Shares opened the trading week at $7.55, and have been paused several times on Friday due to trading volatility. (stephen.nakrosis@wsj.com)
(END) Dow Jones Newswires
August 10, 2018 11:18 ET (15:18 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
